<DOC>
	<DOCNO>NCT00470470</DOCNO>
	<brief_summary>This phase II trial study well imatinib mesylate work treat patient stage III stage IV melanoma remove surgery . Imatinib mesylate may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Imatinib Mesylate Treating Patients With Stage III Stage IV Melanoma That Can Be Removed Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine overall objective response rate ( complete response partial response ) patient inoperable stage III IV melanoma harbor somatic alteration c-KIT treat imatinib mesylate . SECONDARY OBJECTIVES : I . Determine time progression patient treat drug . II . Determine c-KIT mutational status DNA sequencing , DNA copy number status fluorescent situ hybridization ( FISH ) comparative genomic hybridization , and/or protein expression immunohistochemistry ( IHC ) best predict clinical benefit imatinib mesylate . TERTIARY OBJECTIVES : I . To evaluate tumor resistant small molecule inhibitor Kit development secondary Kit mutation change Kit copy number . II . To evaluate change Ki-67 , phospho-Akt , phospho-MEK , phospho-S6 , phospho STAT3 , cleave caspase 3 , IGF-1R , Kit expression pair tumor sample obtain patient treat small molecule inhibitor Kit . III . To analyze baseline post-resistance blood sample soluble cKIT level , soluble VEGFR1 , soluble VEGFR2 , VEGF , PlGF , FGF , melanoma inhibitory activity ( MIA ) level , circulate tumor cell . IV . To analyze concomitant sample blood tumor imatinib level patient treat imatinib . OUTLINE : This multi-center study . Patients stratify accord true amplification c-KIT FISH v mutation DNA sequence . Patients receive oral imatinib mesylate twice daily 12 week absence disease progression unacceptable toxicity . Tumor tissue sample unstained tissue slides/paraffin block may collect . c-KIT evaluate IHC comparative genomic hybridization . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Histologically cytologically confirm inoperable stage III IV melanoma begin acral skin mucosa Patients cutaneous melanoma begin sun expose site skin whose pathology demonstrate sign sun damage ( solar elastosis ) involve skin surround primary melanoma eligible Must sufficient tumor tissue available FISH DNA sequence Patients must either true amplification 4q12 detectable mutation cKIT If bank tumor tissue available , available bank tumor tissue insufficient necessary testing , repeat biopsy procedure require collect necessary tumor sample Measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) criteria No know untreated brain epidural metastasis Brain metastasis treat deem stable allow ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Life expectancy great 3 month WBC ≥ 3,000/mm³ ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Patients unexplained hyperbilirubinemia clinically consistent inherit disorder bilirubin metabolism ( e.g. , Gilbert 's syndrome ) may eligible AST ALT ≤ 2.5 time ULN ( 5 time ULN hepatic metastasis present ) Creatinine ≤ 1.5 time ULN PT PTT ≤ 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception study participation No history allergic reaction attribute compound similar chemical biological composition imatinib mesylate No concurrent uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable anginapectoris Cardiac arrhythmia result hemodynamic instability Intestinal malabsorption disorder Psychiatric illness social situation would limit study compliance Recovered grade 1 prior therapy exception alopecia At least 2 week since prior radiotherapy ( ≤ 3,000 cGy field include substantial marrow ) At least 2 week since prior isolate limb infusion perfusion ( must evidence progression despite therapy ) At least 2 week since prior chemotherapy No 2 prior chemotherapy regimen metastatic melanoma Prior therapy vaccine , target agent believe affect kit protein , cytokine , interferonα , intratumoral injection NOT consider prior therapy unless administer chemotherapy drug No prior therapy inhibitor kit protein No concurrent investigational agent No concurrent anticancer agent therapies No concurrent antiretroviral therapy HIVpositive patient No concurrent inhibitor CYP3A4 , include follow : Fluconazole , itraconazole , ketoconazole , macrolide antibiotic ( azithromycin , clarithromycin , erythromycin , troleandomycin ) , midazolam , nifedipine , verapamil , diltiazem , terfenadine , cyclosporine cisapride Herbal extract tincture CYP3A4 inhibitory activity , include follow : Hydrastis canadensis ( goldenseal ) , Hypericum perforatum ( St. John 's wort ) , Uncaria tomentosa ( cat 's claw ) , Echinacea angustifolia root , Trifolium pratense ( wild cherry ) , Matricaria , chamomilla ( chamomile ) , Glycyrrhiza glabra ( licorice ) , dillapiol , hypericin , naringenin No concurrent inducer CYP3A4 , include follow : Carbamazepine , phenobarbital , phenytoin , rifampin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>